Clinical Validation of KIT Inhibition in Advanced Systemic Mastocytosis

Overview

Journal Curr Hematol Malig Rep

Publisher Current Science

Specialties Hematology
Oncology

Date 2018 Aug 30

PMID 30155614

Citations 8

Authors

John H Baird

Jason Gotlib

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: We discuss recent developments in the treatment of advanced systemic mastocytosis (advSM) with inhibitors of the KIT receptor tyrosine kinase.

Recent Findings: advSM is a heterogeneous group of neoplasms of poor prognosis characterized by the accumulation of neoplastic mast cells. The canonical KIT D816V mutation is present in approximately 90% of SM patients, and its detection is critical for both diagnosis and therapeutic decision-making. The multikinase/KIT inhibitor midostaurin was recently approved for advSM. This agent can reverse SM-related organ damage and disease symptoms, and decrease the bone marrow mast cell burden and splenomegaly. However, complete remissions are rare and durability of responses is variable. Potent and selective KIT D816V inhibitors including avapritinib (BLU-285) and DCC-2618 have entered clinical trials, and rational combination strategies are under development. The clinical efficacy of KIT inhibitors validate KIT as a key oncogenic driver in mast cell neoplasms. An improved understanding of the genetic heterogeneity beyond KIT will help inform the dynamics of response and relapse.

Citing Articles

Prevalence and incidence of mastocytosis in adults: a Danish nationwide register study.

Jorgensen M, Ovlisen A, Jensen J, El-Galaly T, Dalager M, Vestergaard H Eur J Epidemiol. 2025; 40(1):43-53.

PMID: 39751701 PMC: 11799073. DOI: 10.1007/s10654-024-01195-5.

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts.

Valent P, Akin C, Arock M, Gleixner K, Greinix H, Hermine O Int J Mol Sci. 2023; 24(20).

PMID: 37894806 PMC: 10607143. DOI: 10.3390/ijms242015125.

Antineoplastic efficacy profiles of avapritinib and nintedanib in D816V systemic mastocytosis: a preclinical study.

Degenfeld-Schonburg L, Gamperl S, Stefanzl G, Schruef A, Sadovnik I, Bauer K Am J Cancer Res. 2023; 13(2):355-378.

PMID: 36895976 PMC: 9989615.

Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update.

El Hussein S, Chifotides H, Khoury J, Verstovsek S, Thakral B Cancers (Basel). 2022; 14(14).

PMID: 35884535 PMC: 9322501. DOI: 10.3390/cancers14143474.

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers.

Brachet-Botineau M, Polomski M, Neubauer H, Juen L, Hedou D, Viaud-Massuard M Cancers (Basel). 2020; 12(1).

PMID: 31963765 PMC: 7016966. DOI: 10.3390/cancers12010240.

References

Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris M, Hermine O, Damaj G . Mast cell leukemia. Blood. 2012; 121(8):1285-95. DOI: 10.1182/blood-2012-07-442400. View

Fritsche-Polanz R, Jordan J, Feix A, Sperr W, Sunder-Plassmann G, Valent P . Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001; 113(2):357-64. DOI: 10.1046/j.1365-2141.2001.02783.x. View

Alvarez-Twose I, Gonzalez P, Morgado J, Jara-Acevedo M, Sanchez-Munoz L, Matito A . Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol. 2012; 30(12):e126-9. DOI: 10.1200/JCO.2011.38.9973. View

Jawhar M, Schwaab J, Naumann N, Horny H, Sotlar K, Haferlach T . Response and progression on midostaurin in advanced systemic mastocytosis: D816V and other molecular markers. Blood. 2017; 130(2):137-145. DOI: 10.1182/blood-2017-01-764423. View

Zhang L, Smith M, Schultheis B, Fitzgibbon J, Lister T, Melo J . A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2005; 30(4):373-8. DOI: 10.1016/j.leukres.2005.08.015. View

Tan A, Westerman D, McArthur G, Lynch K, Waring P, Dobrovic A . Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem. 2006; 52(12):2250-7. DOI: 10.1373/clinchem.2006.068205. View

Traina F, Visconte V, Jankowska A, Makishima H, OKeefe C, Elson P . Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One. 2012; 7(8):e43090. PMC: 3419680. DOI: 10.1371/journal.pone.0043090. View

Gleixner K, Mayerhofer M, Cerny-Reiterer S, Hormann G, Rix U, Bennett K . KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011; 118(7):1885-98. DOI: 10.1182/blood-2010-06-289959. View

Czechowicz A, Kraft D, Weissman I, Bhattacharya D . Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science. 2007; 318(5854):1296-9. PMC: 2527021. DOI: 10.1126/science.1149726. View

10.

Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M . Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013; 122(14):2460-6. DOI: 10.1182/blood-2013-04-496448. View

11.

Spiegel J, McNamara C, Kennedy J, Panzarella T, Arruda A, Stockley T . Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy. Blood Adv. 2018; 1(20):1729-1738. PMC: 5728340. DOI: 10.1182/bloodadvances.2017009530. View

12.

Soucie E, Hanssens K, Mercher T, Georgin-Lavialle S, Damaj G, Livideanu C . In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells. Blood. 2012; 120(24):4846-9. DOI: 10.1182/blood-2011-12-397588. View

13.

Pardanani A, Elliott M, Reeder T, Li C, Baxter E, Cross N . Imatinib for systemic mast-cell disease. Lancet. 2003; 362(9383):535-6. DOI: 10.1016/s0140-6736(03)14115-3. View

14.

Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J . Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009; 124(3):514-21. DOI: 10.1016/j.jaci.2009.05.003. View

15.

Garcia-Montero A, Jara-Acevedo M, Teodosio C, Sanchez M, Nunez R, Prados A . KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006; 108(7):2366-72. DOI: 10.1182/blood-2006-04-015545. View

16.

Lanternier F, Cohen-Akenine A, Palmerini F, Feger F, Yang Y, Zermati Y . Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One. 2008; 3(4):e1906. PMC: 2292130. DOI: 10.1371/journal.pone.0001906. View

17.

Ustun C, Reiter A, Scott B, Nakamura R, Damaj G, Kreil S . Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol. 2014; 32(29):3264-74. PMC: 4876356. DOI: 10.1200/JCO.2014.55.2018. View

18.

Hochhaus A, Baccarani M, Giles F, le Coutre P, Muller M, Reiter A . Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J Cancer Res Clin Oncol. 2015; 141(11):2047-60. PMC: 4768228. DOI: 10.1007/s00432-015-1988-0. View

19.

Patel K, Newberry K, Luthra R, Jabbour E, Pierce S, Cortes J . Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015; 126(6):790-7. PMC: 4528066. DOI: 10.1182/blood-2015-03-633404. View

20.

Newberry K, Patel K, Masarova L, Luthra R, Manshouri T, Jabbour E . Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017; 130(9):1125-1131. PMC: 5580275. DOI: 10.1182/blood-2017-05-783225. View